TABLE II.
Characteristics of regorafenib treatment in the study population
| Characteristic | Value |
|---|---|
| Therapy before regorafenib [n (%)] | |
| Agent | |
| Thymidylate synthase inhibitor | 35 (100) |
| Irinotecan | 35 (100) |
| Bevacizumab | 31 (89) |
| Oxaliplatin | 28 (80) |
| EGFR inhibitor | 18 (51) |
| Othera | 5 (14) |
| Lines received [n (%)] | |
| 1 | 4 (11) |
| 2 | 13 (37) |
| 3 | 18 (51) |
| Median lines received (n) | 3 |
| Time from diagnosis of metastatic disease | |
| ≤18 Months | 9 (26) |
| >18 Months | 25 (71) |
| Unknown | 1 (3) |
| Regorafenib therapy | |
| Starting dose [n (%)] | |
| 160 mg | 19 (54) |
| 120 mg | 14 (40) |
| 80 mg | 2 (6) |
| Dose modification [n (%)] | |
| Interruption | 10 (29) |
| Reduction | 12 (34) |
| Increase | 5 (14) |
| Interruption and reduction | 10 (29) |
| No modificationb | 18 (51) |
| Best response [n (%)] | |
| Partial response | 0 |
| Stable disease | 6 (17) |
| Progressive disease | 21 (60) |
| Unknown | 8 (23)) |
| Cystic changes on imaging [n (%)] | 5 (14) |
| Worst biochemical level recorded [median (IQR)] | |
| AST | 62 (66) |
| ALT | 33 (33) |
| Bilirubin | 21 (16) |
| Phosphate | 0.77 (0.33) |
| Reason for regorafenib discontinuation [n (%)] | |
| Progressive disease | 18 (51) |
| Toxicity | 9 (26) |
| Still on therapy at study close | 6 (17) |
| Otherc | 1 (3) |
| Unknown | 1 (3) |
a
Other systemic therapies received (alone or in combinations) included aflibercept, BBI503, buparlisib, Reolysin (Oncolytics Biotech Inc., Calgary, AB), and MG1MA3.
b
No modification indicates no interruption, reduction, or increase.
c
Died while on regorafenib without known progressive disease or regorafenib toxicity.
IQR = interquartile range; AST = aspartate aminotransferase; ALT = alanine aminotransferase.